Tabimorelin

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 530201

CAS#: 193079-69-5

Description: Tabimorelin is a growth hormone releasing factor agonist potentially for the treatment of growth hormone deficit. Tabimorelin is a drug which acts as a potent, orally-active agonist of the ghrelin/growth hormone secretagogue receptor (GHSR) and growth hormone secretagogue, mimicking the effects of the endogenous peptide agonist ghrelin as a stimulator of growth hormone (GH) release.


Price and Availability

Size
Price

Size
Price

Size
Price

Tabimorelin is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 530201
Name: Tabimorelin
CAS#: 193079-69-5
Chemical Formula: C32H40N4O3
Exact Mass: 528.31
Molecular Weight: 528.697
Elemental Analysis: C, 72.70; H, 7.63; N, 10.60; O, 9.08


Synonym: Tabimorelin, NN-703, NNC-26-0703, NNC-260703, NN703, NNC26-0703, NNC260703

IUPAC/Chemical Name: (E)-5-amino-N,5-dimethyl-N-((R)-1-(methyl((R)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl)amino)-3-(naphthalen-2-yl)-1-oxopropan-2-yl)hex-2-enamide

InChi Key: WURGZWOTGMLDJP-ZCYANPAGSA-N

InChi Code: InChI=1S/C32H40N4O3/c1-32(2,33)19-11-16-29(37)35(4)28(22-24-17-18-25-14-9-10-15-26(25)20-24)31(39)36(5)27(30(38)34-3)21-23-12-7-6-8-13-23/h6-18,20,27-28H,19,21-22,33H2,1-5H3,(H,34,38)/b16-11+/t27-,28-/m1/s1

SMILES Code: CC(C)(N)C/C=C/C(N(C)[C@@H](C(N(C)[C@@H](C(NC)=O)CC1=CC=CC=C1)=O)CC2=CC=C3C=CC=CC3=C2)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Shimatsu A. [Ghrelin-related drugs: clinical perspectives]. Nihon Rinsho. 2004 Sep;62 Suppl 9:435-8. Review. Japanese. PubMed PMID: 15506422.

2: Holm AM, Johansen PB, Ahnfelt-Rønne I, Rømer J. Adipogenic and orexigenic effects of the ghrelin-receptor ligand tabimorelin are diminished in leptin-signalling-deficient ZDF rats. Eur J Endocrinol. 2004 Jun;150(6):893-904. PubMed PMID: 15191361.

3: Svensson J, Monson JP, Vetter T, Hansen TK, Savine R, Kann P, Bex M, Reincke M, Hagen C, Beckers A, Ilondo MM, Zdravkovic M, Bengtsson BA, Korbonits M; NN703 Clinical Research Group.. Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency. Clin Endocrinol (Oxf). 2003 May;58(5):572-80. PubMed PMID: 12699438.

4: Zdravkovic M, Olsen AK, Christiansen T, Schulz R, Taub ME, Thomsen MS, Rasmussen MH, Ilondo MM. A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate. Eur J Clin Pharmacol. 2003 Feb;58(10):683-8. PubMed PMID: 12610745.

5: Nielsen KK, Buddington KK, Raun K, Hansen TK, Buddington RK. Absorption and systemic availability of two synthetic growth hormone secretogogues and transport of glucose by the proximal small intestine of anestrus dogs after administering estradiol. J Comp Physiol B. 2003 Feb;173(1):61-7. PubMed PMID: 12592444.

6: Peschke B, Ankersen M, Bauer M, Hansen TK, Hansen BS, Nielsen KK, Raun K, Richter L, Westergaard L. The influence of conformational restriction in the C-terminus of growth hormone secretagogues on their potency. Eur J Med Chem. 2002 Jun;37(6):487-501. PubMed PMID: 12204475.

7: Malmlöf K, Bauer MK, Johansen PB, Ankersen M, Veldhuis JD. Daily low-dose administration of growth hormone secretagogue stimulates pulsatile growth hormone secretion and elevates plasma insulin-like growth factor-1 levels in pigs. Endocrine. 2001 Dec;16(3):195-9. PubMed PMID: 11954663.

8: Hansen TK, Ankersen M, Raun K, Hansen BS. Highly potent growth hormone secretagogues: hybrids of NN703 and ipamorelin. Bioorg Med Chem Lett. 2001 Jul 23;11(14):1915-8. PubMed PMID: 11459660.

9: Zdravkovic M, Christiansen T, Eliot L, Agersoe H, Thomsen MS, Falch JF, Søgaard B, Ynddal L, Ilondo MM. The pharmacokinetics, pharmacodynamics, safety and tolerability following 7 days daily oral treatment with NN703 in healthy male subjects. Growth Horm IGF Res. 2001 Feb;11(1):41-8. PubMed PMID: 11437473.

10: Ahnfelt-Rønne I, Nowak J, Olsen UB. Do growth hormone-releasing peptides act as ghrelin secretagogues? Endocrine. 2001 Feb;14(1):133-5. PubMed PMID: 11322495.

11: Agersø H, Ynddal L, Søgaard B, Zdravkovic M. Pharmacokinetic and pharmacodynamic modeling of NN703, a growth hormone secretagogue, after a single po dose to human volunteers. J Clin Pharmacol. 2001 Feb;41(2):163-9. PubMed PMID: 11210396.

12: Zdravkovic M, Christiansen T, Grosch K, Ilondo MM. Evaluation of the conformity of human growth hormone concentrations measured with the DPC Immulite and the Nichols Advantage assays. Clin Chem Lab Med. 2000 Aug;38(8):799-800. PubMed PMID: 11071076.

13: Zdravkovic M, Søgaard B, Ynddal L, Christiansen T, Agersø H, Thomsen MS, Falch JE, Ilondo MM. The pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of NN703, a novel orally active growth hormone secretagogue in healthy male volunteers. Growth Horm IGF Res. 2000 Aug;10(4):193-8. PubMed PMID: 11032702.

14: Peschke B, Ankersen M, Hansen TK, Hansen BS, Lau J, Nielsen KK, Raun K. New highly potent dipeptidic growth hormone secretagogues with low molecular weight. Eur J Med Chem. 2000 Jun;35(6):599-618. PubMed PMID: 10906412.

15: Ankersen M, Kramer Nielsen K, Kruse Hansen T, Raun K, Sehested Hansen B. Growth hormone secretagogues derived from NN703 with hydrazidesas c-terminal. Eur J Med Chem. 2000 May;35(5):487-97. PubMed PMID: 10889328.

16: Hansen BS, Raun K, Nielsen KK, Johansen PB, Hansen TK, Peschke B, Lau J, Andersen PH, Ankersen M. Pharmacological characterisation of a new oral GH secretagogue, NN703. Eur J Endocrinol. 1999 Aug;141(2):180-9. PubMed PMID: 10427162.

17: Peschke B, Hansen BS. New growth hormone secretagogues: C-terminal modified sulfonamide-analogues of NN703. Bioorg Med Chem Lett. 1999 May 3;9(9):1295-8. PubMed PMID: 10340617.